Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors by Keng Lam, MD, Lewis F. Nasr, MD, Clark R. Andersen, MS, Kathryn E. Marqueen, MD, Jing Li, MD, PhD, Chenyang Wang, MD, Thomas H. Beckham, MD, PhD, Nazanin K. Majd, MD, PhD, Ashley E. Aaroe, MD, Monica Loghin, MD, Barbara J. O'Brien, MD, Susan L. McGovern, MD, PhD

“…Breast cancer (53%), lung cancer (20%), and melanoma (9%) were the most common primary cancers; 51% of patients had stable systemic disease at LM diagnosis. …”
Get full text

Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy by Patrick Hwu, Ravi Murthy, Aung Naing, Sapna P. Patel, Simon Young, Alda Tam, Nina M. Muñoz, Malea Williams, Katherine Dixon, Crystal Dupuis, Amanda McWatters, Rony Avritscher, Soraya Zorro Manrique, Kevin McHugh, David Leach, Jeffrey D. Hartgerink, Punit Prakash, Rahul A. Sheth

“…Evaluation of tumor stroma on intratumoral drug delivery revealed that there was a greater than twofold improvement in intratumoral distribution in soft tumors (B16 melanoma) compared with firm tumors (MC38 colorectal).Conclusions Injection technique, drug formulation and tumor stiffness play key roles in the accurate delivery of intratumoral immunotherapeutics.…”
Get full text

Knowledge, Attitude, and Practice (KAP) Survey toward Skin Cancer among Ecuadorian Population by Victor H. Pinos-León, César Sandoval, Franklin Cabrera, Esmeraldas Terán, Ana Garnica, Ana Kellendonk, Mery Alvear, Carla Rosero, Lorena Vaca, Jorge Bonifaz, Anita Buestán, Claudia Armas, Raquel Trujillo, Patricio Freire, Tamara León, Giselle Erazo, Liliana García, Marcela Alzate, Vicente Toapanta, Myriam Ortega, Daniela Caicedo, Alicia Pereira, Lenin Gómez-Barreno, Juan S. Izquierdo-Condoy, Merry Charlie, Esteban Ortiz-Prado, Katherine Simbaña-Rivera

“…Skin cancer is one of the most common cancers, and melanoma is a highly preventable cancer. In Ecuador, few studies have evaluated the awareness levels of the population about the disease. …”
Get full text

Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies by Iza Andrade de A. Souza, Beatriz de M. Dobbert, Barbara G. Sao Jose, Joao Pedro Homse-Netto, Larissa L. Furlan, Maira S. Abreu, Camila Ferrari, Bruno Uchoa, Kathia Abdallah, Stephano N. Lucio, Joao A. Soler, Fabio L.C. Fernandez, Luiza Ferreira, Joao D. Guedes, Aline F. Fares, Daniel V. Araujo

“…The most frequent tumor sites were the lung (41% LD, 22.9% CD) and skin (melanoma; 24.6% LD, 50% CD). Most of the patients were treated with pembrolizumab (65% LD and 72% CD). …”
Get full text

Clinical characteristics and prognosis of amyopathic dermatomyositis patients with interstitial lung disease: insights from a retrospective cohort by Yanan Ying, Tingting Wu, Long Wang, Yun Zhang, Yiming Yu, Zaichun Deng, Qunli Ding

“…Cox multivariate analysis revealed that age (p = 0.002), smoking status (p = 0.011), anti-melanoma differentiation-associated gene 5 (MDA5) antibody (p = 0.017), and white blood cell count (p = 0.004) were independent predictors of shorter survival. …”
Get full text

Changes in cancer incidence and stage during the COVID-19 pandemic in 2020–2021 in the Nordic countries by Anna Johansson, Anna Skog, Tom Børge Johannesen, Tor Åge Myklebust, Simon M. Kønig, Charlotte Wessel Skovlund, Lina Steinrud Mørch, Søren Friis, Marnar Fríðheim Kristiansen, David Pettersson, Eva María Gudmundsdóttir, Nanna Margrét Kristinsdóttir, Helgi Birgisson, Sandra Irenaeus, Johan Ahlgren, Mats Lambe, Elli Hirvonen, Janne Pitkäniemi, Giske Ursin

“…Prostate cancer rates declined in Denmark/Finland/Norway/Sweden during 2020–2021, while melanoma rates declined in Finland in 2020. During 2020, colon cancer rates declined in Denmark and Iceland, while rectal cancer rates declined in Denmark, and lung and kidney cancer rates declined in Norway. …”
Get full text

Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes by Kazuhiro Kakimi, Hirokazu Matsushita, Masaaki Komatsu, Eiryo Kawakami, Mikako Nishida, Nahoko Yamashita, Taisaku Ogawa, Keita Koseki, Eiji Warabi, Tomoyuki Ohue, Katsuyuki Shiroguchi, Heiichiro Udono

“…RNA sequencing was performed for CD8TILs and tumor cells. Melanoma cells containing an IFN-γ receptor (IFNγR) cytoplasmic domain deletion mutant was overexpressed and used for characterization of the metabolic profile of those tumor cells using a Seahorse Flux Analyzer.Results Met administration elevates mtROS and cell surface Glut-1, resulting in the production of IFN-γ in CD8TILs. mtROS activates Nrf2 in a glycolysis-dependent manner, inducing activation of autophagy, glutaminolysis, mTORC1, and p62/SQSTM1. mTORC1-dependent phosphorylation of p62 at serine 351 (p-p62(S351)) is also involved in activation of Nrf2. …”
Get full text

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... by Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman

“…This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.Methods Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castration-resistant prostate cancer, or melanoma in part A (V937 monotherapy), and metastatic NSCLC or urothelial cancer in part B (V937+pembrolizumab). …”
Get full text

Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy by Yishen Tian, Jingxuan Li, Na Yang, Yang Zhao, Jiancao Zuo, Hang Xiong, Yiwen Pan, Li Xiao, Min Su, Feng Han, Zhixu He, Rong Hu

“…Experimental results demonstrated that this cellular preparation exhibited promising therapeutic effects in both melanoma and pancreatic cancer models. This research provided a novel platform for the synergistic cooperation of various methods in tumor immunotherapy, holding broad application prospects.…”
Get full text

Iodine activates NLRP3 inflammasomes in PBMCs of patients with autoimmune thyroiditis and regulates Th1 and Th17 cell differentiation by Ying Wu, Qingling Guo, Yongping Liu, Xun Gong, Wei Sun, Yushu Li, Chenling Fan, Weiping Teng, Zhongyan Shan

“…., NLRP1, NLRP3, absent in melanoma 2 (AIM2) and caspase-1), interleukin (IL)-1β and IL-18 were assessed using qRT-PCR and western blotting. …”
Get full text

Regional hyperthermia for soft tissue sarcoma – a survey on current practice, controversies and consensus among 12 European centers by Siyer Roohani, Felix Ehret, Marcus Beck, Danai P. Veltsista, Jacek Nadobny, Sebastian Zschaeck, Sultan Abdel-Rahman, Franziska Eckert, Anne Flörcken, Rolf D. Issels, Stephan Klöck, Robert Krempien, Lars H. Lindner, Markus Notter, Oliver J. Ott, Daniel Pink, Vlatko Potkrajcic, Peter Reichardt, Oliver Riesterer, Mateusz Jacek Spałek, Emanuel Stutz, Rüdiger Wessalowski, Thomas Zilli, Daniel Zips, Pirus Ghadjar, David Kaul

Get full text

Transferrin Disassociates TCR from CD3 Signaling Apparatus to Promote Metastasis by Ruomei Cheng, Xiaopeng Tang, Qiyu Zhao, Yuming Wang, Wenlin Chen, Gan Wang, Chenxi Wang, James Mwangi, Qiumin Lu, Dawit Adisu Tadese, Xudong Zhao, Caiwen Ou, Ren Lai

“…Here, we report that transferrin, which is overexpressed in patients with liver metastasis, disassociates TCR from the CD3 signaling apparatus by targeting the constant domain (CD) of T cell receptor α (TCRα), consequently suppresses T cell activation, and inhibits anti-metastatic and anti-tumor immunity. In mouse models of melanoma and lymphoma, transferrin overexpression exacerbates liver metastasis, while its knockdown, antibody, designed peptides, and CD mutation interfering with transferrin–TCRα interaction inhibit metastasis. …”
Get full text

Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy by James Dooley, Bart Neyns, Elizabeth Allen, Frank Tacke, Louis Boon, Damya Laoui, Julia Katharina Schwarze, Helena Van Damme, Bruno Dombrecht, Máté Kiss, Heleen Roose, Eva Van Overmeire, Daliya Kancheva, Liesbet Martens, Aleksandar Murgaski, Pauline Madeleine Rachel Bardet, Gillian Blancke, Maude Jans, Evangelia Bolli, Maria Solange Martins, Yvon Elkrim, Kiavash Movahedi, Niels Vandamme, Sebahat Ocak, Isabelle Scheyltjens, Lars Vereecke, Frank Aboubakar Nana, Pascal Merchiers, Jo Agnes Van Ginderachter

“…These findings were validated by flow cytometric analysis of both mouse (LLC-OVA, MC38 and B16-OVA) and human (NSCLC and melanoma) tumor samples. We generated two CCR8-specific nanobodies (Nbs) that recognize distinct epitopes on the CCR8 extracellular domain. …”
Get full text

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

“…We investigated the safety and tolerability of IMA202 in a first-in-human, dose escalation basket trial in human leucocyte antigen A*02:01 positive patients with melanoma-associated antigen A1 (MAGEA1)-positive advanced solid tumors.Trial design The 2+2 trial design was an algorithmic design based on a maximally acceptable dose-limiting toxicity (DLT) rate of 25% and the sample size was driven by the algorithmic design with a maximum of 16 patients. …”
Get full text

Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins by Maria Angelica Freitas-Cortez, Fatemeh Masrorpour, Hong Jiang, Iqbal Mahmud, Yue Lu, Ailing Huang, Lisa K. Duong, Qi Wang, Tiffany A. Voss, Claudia S. Kettlun Leyton, Bo Wei, Wai-Kin Chan, Kevin Lin, Jie Zhang, Efrosini Tsouko, Shonik Ganjoo, Hampartsoum B. Barsoumian, Thomas S. Riad, Yun Hu, Carola Leuschner, Nahum Puebla-Osorio, Jing Wang, Jian Hu, Michael A. Davies, Vinay K. Puduvalli, Cyrielle Billon, Thomas P. Burris, Philip L. Lorenzi, Boyi Gan, James W. Welsh

Get full text

Analysis of single nucleotide polymorphism of p16 gene in cytological samples of patients with oral potentially malignant disorders (OPMD) and oral squamous cell carcinoma (OSCC) by Neetu Oommen, Vasanthi V, Ramya Ramadoss, Rajkumar Krishnan

“…Frequent homozygous deletions of the pl6 gene have been reported in many tumor cell lines including the brain, breast, osteosarcomas, melanomas, kidney, bladder, and ovary. Materials and methods: 5 patients without any tobacco using habit were included in group I as controls. 10 clinically and histopathologically confirmed cases of oral potentially malignant disorders (OPMDs) [oral submucous fibrosis (OSMF) −7 & leukoplakia (moderate dysplasia) −3] were included in group II. 10 clinically and histopathologically confirmed cases of OSCC were categorized as group III. …”
Get full text

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report by Yasar Subutay Peker, Mehmet Fatih Can, Ismail Hakki Ozerhan, Gokhan Yagci, Nazif Zeybek, Kutan Kavakli, Sedat Gurkok, Alper Gozubuyuk, Onur Genc, Gokhan Erdem, Ahmet Ozet, Mustafa Gerek, Yusuf Peker

“…BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. …”
Get full text

Malignant and Noninvasive Skin Tumours in Renal Transplant Recipients by Christopher D. Roche, Joelle S. Dobson, Sion K. Williams, Mara Quante, Joyce Popoola, Jade W. M. Chow

“…Additionally, 21 patients (3.0%) only had noninvasive tumours. 221 malignant skin tumours were found: 50.2% were SCCs, 47.1% BCCs, and 2.7% malignant melanomas. Mean years to first tumour were 5.8. Mean number of tumours per patient was 4, with mean interval of 12 months. …”
Get full text

Topical Mitomycin C and Radiation Induce Conjunctival DNA-Polyploidy by Olaf Cartsburg, Christopher Kallen, Jost Hillenkamp, Rainer Sundmacher, Natalia Pomjanski, Alfred Böcking

“…Methods: Conjunctival brush smears were obtained from 13 patients (13 eyes) with squamous cell carcinomas and six patients (6 eyes) with conjunctival malignant melanomas in situ before, during and after treatment. …”
Get full text

The burden of medical contraindications to corneal donation: Time for review. by Oliver Dorado-Cortez, Sylvain Poinard, Magali Epinat, Fanny Collange, Sandrine Ninotta, Paul Goin, Jean Luc Perrot, Philippe Gain, Graeme Pollock, Gilles Thuret

“…The list of medical contraindications (CI) to corneal donation also includes diseases for which no actual, only theoretical, risk has been identified, in particular, neurodegenerative diseases, hematological malignancies, melanomas, tumors of the central nervous system, neoplastic meningitis and lymphangitic carcinomatosis. …”
Get full text